Rucaparib for prostate cancer – pro
This is an experimental drug, being explored in the TRITON2 study (NCT02952534) is a multicenter, open-label Phase 2 clinical trial to evaluate the effects of rucaparib in about 160 patients with mCRPC who have a deleterious mutation in BRCA1, BRCA2, ATM, or another pre-specified DNA repair gene. Eligible patients must have progressed on at least one, but no more than two, the previous androgen-receptor targeted therapies and one prior taxane-based chemotherapy. The study’s primary outcome is response rate to the drug, both objective response and prostate-specific antigen response. The study was recently closed but the results are not yet published. It is also in the Study of Rucaparib Versus Physician’s Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3), NCT02975934. Preliminary results were presented s a poster in ASCO 2018.
A related drug olaparib recently showed activity in phase 2 TOPARP-B trial.
Joaquin Mateo, M.D., Suzanne Carreira, Ph.D., Shahneen Sandhu, M.D., Susana Miranda, B.Sc., Helen Mossop, M.Math.Stat., Raquel Perez-Lopez, M.D., Daniel Nava Rodrigues, M.D., Dan Robinson, Ph.D., Aurelius Omlin, M.D., Nina Tunariu, M.D.Res., Gunther Boysen, Ph.D., Nuria Porta, Ph.D., et al.DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.N Engl J Med 2015; 373:1697-1708
Preliminary Results from TRITON2: A Phase 2 Study of Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Associated with Homologous Recombination Repair (HRR) Gene Alterations- https://clovisoncology.com/media/1127/rucaparib_wabida_poster_esmo2018.pdf